EFFECTS OF NITRIC OXIDE SYNTHASE INHIBITOR (L-NAME) ON CYTOPATHOLOGIC CHANGES DUE TO CHOLESTASIS IN HEPATIC CELLS OF ADULT MALE RATS

Alireza Monsef

Department of Pathology, Hamadan University of Medical Sciences, Hamadan, Iran

Introduction

Obstructive cholestasis is associated with overproduction of endogenous opioids, nitric oxide (NO) and cytokines in the bloodstream. Nitro-L-arginine methyl ester (L-NAME) administration decreases the NO serum level and it is able to reduce related complications. The aim of this research is to survey the effects of the NO inhibitor on complications relating to cholestasis in liver cells and intrahepatic biliary ducts. We used five groups of animals: control, sham-operated (surgical control), bile duct ligated (BDL) group, BDL and normal saline infused group, and BDL with L-NAME administrated group. After 3 weeks all animals were killed, histopathology of liver cells and intrahepatic biliary ducts were evaluated by hematoxylin-eosin (HE), PAS (periodic acid-Schiff) and trichrome staining. The status of inflammation and fibrosis was evaluated by the modified Knodell score system. Microscopic study of different groups showed that the necro-inflammatory score in the control group was 0.36, it was 1 in the sham-operated group and it raised to 15.2 in the cholestatic group. After administration of L-NAME it had a meaningful decrease to 7, but in the saline-treated group, the score was 16. L-NAME with the mentioned dose was capable of decreasing the serum nitric oxide level, although it is able to decrease the unfavorable complications of cholestatic jaundice.

Key words: nitric oxide synthase, pathology, cholestasis, liver.
1999, El-Gohary et al. studied the effect of Voltametrin on apoptosis of rat testicular cells. Voltametrin caused serum NO to rise, in addition, the testicular cells showed apoptosis and inhibition of spermatogenesis. Nitric oxide synthase inhibitor drug (nitro-L-arginine methyl ester – L-NAME) at a dose of 1 mg/kg reduced these harmful effects [3].

In 2001, Mani et al. showed the effect of naloxone (opioid inhibitor) on the rats with cholestasis. It will protect the stomach from indometacin side effects [1]. Namiranian et al. displayed that nitric oxide synthase inhibitor (L-NAME) at a dose of 1 mg/kg did not have any effect on complications of cholestasis [4].

In this study we surveyed the effects of cholestasis on the liver and the effect of L-NAME as a nitric oxide synthase inhibitor on histopathologic changes of the mentioned cases.

Material and methods

The study is an experimental study. It was performed at the Histology Department of the Tehran University of Medical Sciences and Hamadan University of Medical Sciences in 2002 to 2003.

Animals and treatment

Male white Sprague-dawley healthy rats between 200 and 250 grams were used. All animals had free access to food and water. The animals were treated according to the criteria defined in the “Guide for the Care and Use of Laboratory Animals” (NIH US publication 86-23 revised 1985). 30 rats were randomly assigned to 5 experimental groups:

- I – control (untreated) group: control animals were kept under the same conditions as experimental groups, but treated without any drug;
- II – sham-operated group: rats with abdominal surgery but without bile duct ligation;
- III – Bile duct ligated (BDL) group: rats with abdominal surgery and bile duct ligation;
- IV – BDL and normal saline infused group: bile duct ligated rats infused with 1 mg/kg normal saline;
- V – BDL and L-NAME administered group: each rat was given 1 mg/kg of L-NAME daily for 21 days.

Materials

L-NAME as a nitric oxide synthase inhibitor was provided by Sigma-Aldrich (Sigma, St. Louis, MO, USA).

Histological assessment of the grades of hepatitis and fibrosis

Liver tissue sections were stained with HE, PAS and trichrome, then evaluated for the grades of inflammation and fibrosis. The status of inflammation and fibrosis was evaluated by the modified Knodell score system with the score ranging from 0 to 24 in this system. The status of inflammation was evaluated with a grading system of total 0-18:

- 1 – piecemeal necrosis (0-4),
- 2 – confluent necrosis (0-6),
- 3 – focal (spotty) lytic necrosis, apoptosis and focal inflammation (0-4),
- 4 – portal inflammation (0-4).

The status of fibrosis was evaluated with a staging system ranging 0-6:

- stage 0: no fibrosis,
- stage 1: fibrous expansion of some portal areas, with or without short fibrous septa,
- stage 2: fibrous expansion of most portal areas, with or without short fibrous septa,
- stage 3: fibrous expansion of most portal areas with occasional portal to portal bridging,
- stage 4: fibrous expansion of portal areas with marked portal-portal (p-p) as well as portal-central (p-c) bridging,
- stage 5: marked bridging (p-p and/or p-c) with occasional nodules (incomplete cirrhosis),
- stage 6: cirrhosis, probable or definite.

According to this scoring system of z modified histological activity index, grading: necroinflammatory scores range from 0 to 18 and for the staging of architectural changes, fibrosis, and cirrhosis, a range of scores of 0 to 6 is considered. U test was used to analyze the scores achieved in each category between rat groups.

Results

The control group of rats’ livers presents normal lobular pattern, portal triads and cellular elements. They had a score of 2 and their mean was 0.33 of 24 (Table I). The sham-operated group was also similar to the control group and there were no significant differences between them. Their cumulative score was 6 and their mean was 0.5. All of the 6 cases of the BDL group reveal distorted lobular architecture. There was severe mononuclear infiltration in the majority of cases in the portal and periportal area, piecemeal necrosis and apoptosis, but in some cases it was moderate. All of them revealed a few necrotic hepatocytes and mild to moderate fibrosis and edema also has been noted. There were apoptotic hepatocytes, whereas bile duct hyperplasia was not revealed. About half of the hepatocytes showed bile pigment and bile duct hyperplasia was seen in 2 out of 6 cases and the other 4 cases showed severe bile duct hyperplasia. There was no difference in binuclear hepatocytes in comparison to the control group. We found multinuclear hepatocytes in 2 cases. Their overall score was 91 and the mean was 15.2 of 24 (Table II).

The fourth group which received daily injections of normal saline after cholestasis, did not show signi-
ficant differences as compared to the cholestasis group. We found distorted lobular architecture, severe portal inflammation, necrosis, apoptosis and bile duct hyperplasia. Their cumulative score was 97 and mean score was 16 of 24. The fifth group received daily L-NAME after cholestasis. The cholestasis had markedly diminished. The lobular architecture had been preserved in 5 out of 6 cases and in one of them it was relatively normal. The portal inflammation was mild in 4 out of 6 cases and 2 of them no inflammation was revealed. There was no necrosis and fibrosis in any section. Apoptosis was found at a rate of 3 to 4 cells in every lobule and bile duct epithelial cells intended for apoptosis. Bile duct hyperplasia was noted to a moderate to severe degree. The cumulative score of this group was 41 and mean score was 6.83 of 24 (Table III).

Table I. Necro-inflammatory scores in the control group of rats

<table>
<thead>
<tr>
<th>CASE</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piecemeal necrosis (0-4)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Confluent necrosis (0-6)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Focal lytic necrosis &amp; apoptosis (0-4)</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Portal inflammation (0-4)</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Architectural changes &amp; fibrosis (0-6)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Sum</strong></td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td>0.33 (SD = 0.81)</td>
<td>0.33 (SD = 0.81)</td>
<td>0.33 (SD = 0.81)</td>
<td>0.33 (SD = 0.81)</td>
<td>0.33 (SD = 0.81)</td>
<td>0.33 (SD = 0.81)</td>
</tr>
</tbody>
</table>

Table II. Necro-inflammatory score in the cholestatic group

<table>
<thead>
<tr>
<th>CASE</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piecemeal necrosis (0-4)</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Confluent necrosis (0-6)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Focal lytic necrosis &amp; apoptosis (0-4)</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Portal inflammation (0-4)</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Architectural changes &amp; fibrosis (0-6)</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>Sum</strong></td>
<td>14</td>
<td>15</td>
<td>13</td>
<td>17</td>
<td>17</td>
<td>15</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td>15.16 (SD = 1.6)</td>
<td>15.16 (SD = 1.6)</td>
<td>15.16 (SD = 1.6)</td>
<td>15.16 (SD = 1.6)</td>
<td>15.16 (SD = 1.6)</td>
<td>15.16 (SD = 1.6)</td>
</tr>
</tbody>
</table>

Table III. Necro-inflammatory score in the L-NAME treated group

<table>
<thead>
<tr>
<th>CASE</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piecemeal necrosis (0-4)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Confluent necrosis (0-6)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Focal lytic necrosis &amp; apoptosis (0-4)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Portal inflammation (0-4)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Architectural changes &amp; fibrosis (0-6)</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Sum</strong></td>
<td>9</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td>6.83 (SD = 2.22)</td>
<td>6.83 (SD = 2.22)</td>
<td>6.83 (SD = 2.22)</td>
<td>6.83 (SD = 2.22)</td>
<td>6.83 (SD = 2.22)</td>
<td>6.83 (SD = 2.22)</td>
</tr>
</tbody>
</table>

Significant differences as compared to the cholestasis group. We found distorted lobular architecture, severe portal inflammation, necrosis, apoptosis and bile duct hyperplasia. Their cumulative score was 97 and mean score was 16 of 24. The fifth group received daily L-NAME after cholestasis. The cholestasis had markedly diminished. The lobular architecture had been preserved in 5 out of 6 cases and in one of them it was relatively normal. The portal inflammation was mild in 4 out of 6 cases and 2 of them no inflammation was revealed. There was no necrosis and fibrosis in any section. Apoptosis was found at a rate of 3 to 4 cells in every lobule and bile duct epithelial cells intended for apoptosis. Bile duct hyperplasia was noted to a moderate to severe degree. The cumulative score of this group was 41 and mean score was 6.83 of 24 (Table III).

Portal inflammation and fibrosis in the cholestatic group was significantly higher than in the normal group using U test, t = 0.0035 and t = 0.0025, respectively (Figs. 1 and 2). Lobular inflammation and liver fibrosis were meaningfully higher in the cholestatic group as compared to the L-NAME treated group, t = 0.0044 and t = 0.0063, respectively. The necroinflammatory score changes of three rat groups are summarized in Fig. 3.

Discussion

Cholestasis induced in rats by ligation of the common bile duct was categorized into five groups for evaluation of nitric oxide synthase effects. We have used the modified Knodell score numeral system for grading and staging of liver injury as an alternative to terms usually used in hepatology such as chronic persistent hepatitis (CPH), chronic active hepatitis (CAH) and chronic lobular hepatitis (CLH), and cirrhosis to nu-
Numerical system (0-24) and statistically analyzed them according to the method described elsewhere [5-7].

The data of previous studies suggested that cholestasis increases the levels of opioids, nitric oxide (NO) and cytokines in serum. It also decreases the concentration of FSH, LH and the testosterone level [8]. Nitric oxide is harmful to Leydig cells. The study of Swain et al. did not reveal the effects of L-NAME in 1 mg/kg dosage on cholestasis complications [8]. Another study showed that oxidative stresses had markedly increased in cholestatic and diabetic patients, and it may be due to inhibition of anti-oxidative activity by hyperglycemia [9]. This study shows that cholestasis results in an architectural distortion of liver structure, intrahepatic bile duct proliferation, accumulation of bile pigments in hepatocytes and liver cell apoptosis. In our study, the cholestasis leads to a 9-point increase of the Knodell score in the BDL group comparing to the control group of rats; the difference was marked and meaningful. In fact, the cholestasis caused a status similar to CAH in the BDL rats’ livers.

Fibrosis and portal inflammation were higher in the cholestatic group than the normal group in our study. Apoptosis or programmed liver cell necrosis is not only dependent on cholestasis, but the increased apoptosis rate in the cholestatic rat group (in comparison to the normal group) suggests the effective role of cholestasis.

The results of our study showed that 1 mg/kg dosage of L-NAME decreased apoptosis by about 50% in the liver. The Knodell score was 0.36/24 in the normal group, 1/24 in sham-operated and 15.2/24 in the cholestatic group. In the L-NAME treated group, the score was 7/24. The changes modified the pathological status of rat liver from CAH in the BDL group to CPH in the L-NAME treated group. Lobular inflammation and fibrosis were meaningfully improved in the L-NAME treated group in comparison to the cholestatic group. These findings are similar to results reported by other investigators [10-12].

In 1999, El-Gohary et al. [3] demonstrated that administration of Deltametrine increases nitric oxide concentration in serum and leads to apoptosis in rat testis. The administration of L-NAME at 1 mg/kg dose decreased apoptosis [3]. Other studies indicated that administration of guanidine as a nitric oxide inhibitor reduces the rate of apoptosis [4, 13]. In this study, Namiranian et al. showed that L-NAME at 1 mg/kg dosage did not have meaningful effects on the testis of cholestatic rats.

Del Punta et al. [14] and Navarro [13] concluded that an increased level of nitric oxide in the process of obstructive jaundice leads to a reduction in cellular energy via impairment in the mitochondrial function.

Therefore, any agent that has the capacity of normalizing the nitric oxide level would be able to decrease the destructive process of cholestasis. Our study displayed the effectiveness of L-NAME in rat liver cells. It decreased cholestatic complications, portal inflam-
mation and also promotes tissue structure whereas tissue necrosis is diminished. Our findings suggest that L-NAME with the mentioned dose is capable of decreasing the serum nitric oxide level, and thus it is able to decrease the unfavorable complications of cholestatic jaundice.

The author wishes to thank Mr. Moradi, Dr. Nasiri, Dr. Noori for their cooperation in the research process and the Hamadan University of Medical Sciences for the financial support. I also wish to thank the Farzan Institute for Research and Technology for technical assistance.

The author declares no conflict of interest.

References

5. Ishak KG. Chronic hepatitis, Morphology and nomenclature. Mod Pathol 1994; 7: 690-713.
9. Rosai and Ackerman's Surgical Pathology. 6th ed. 2002; 682.

Address for correspondence

Alireza Monsef
P.O.Box: 13185-1678
Tehran, Iran
tel. +9821 66439463
fax +9821 66423304
e-mail: monsef_ar2001@yahoo.com